Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

(2022) Alexander X. Lozano et al.   NATURE MEDICINE

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

(2022) Niklas Klümper et al.   Journal for ImmunoTherapy of Cancer

Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade

(2022) Fiamma Berner et al.   Science Immunology

Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes

(2020) Ekaterina Friebel et al.   CELL

Immune-related adverse events of checkpoint inhibitors

(2020) Manuel Ramos-Casals et al.   Nature Reviews Disease Primers

Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients

(2020) Emilio Francesco Giunta et al.   Scientific Reports

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors

(2020) Xiao-Hui Jia et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors

(2019) Kyung Hwan Kim et al.   CLINICAL CANCER RESEARCH

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

(2019) Yosuke Togashi et al.   Nature Reviews Clinical Oncology

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

(2019) Tuba N. Gide et al.   CANCER CELL

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

Development, application and computational analysis of high-dimensional fluorescent antibody panels for single-cell flow cytometry

(2019) Jolanda Brummelman et al.   Nature Protocols

Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review

(2019) Shaheen Khan et al.   SEMINARS IN CANCER BIOLOGY

Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors

(2019) Fausto Petrelli et al.   JOURNAL OF IMMUNOTHERAPY

Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

(2019) David Bomze et al.   JAMA Oncology

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

(2019) Imran G. House et al.   CLINICAL CANCER RESEARCH

CytoNorm: A Normalization Algorithm for Cytometry Data

(2019) Sofie Van Gassen et al.   CYTOMETRY PART A

Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors

(2019) Sophia C Weinmann et al.   RHEUMATOLOGY

Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy

(2019) Yi-He Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy

(2018) Ryuma Tokunaga et al.   CANCER TREATMENT REVIEWS

Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity

(2018) Nathan Karin et al.   CYTOKINE

Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead

(2018) Pradnya D. Patil et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

(2018) Su Y. Lim et al.   CLINICAL CANCER RESEARCH

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulatory T cells in cancer immunotherapy

(2016) Atsushi Tanaka et al.   CELL RESEARCH

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

(2015) Z. Sun et al.   CANCER RESEARCH

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Platinum-conjugated antibodies for application in mass cytometry

(2015) Henrik E. Mei et al.   CYTOMETRY PART A

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE